Palantir's stock is seeing a boost from reports that the U.S. and Saudi Arabian governments have reached a new deal that ...

Palantir stock tumbled Tuesday as investors scrutinized the company's high valuation and declining sales to international ...

Palantir stock has been on a tear in 2025, rising more than 40% even after Tuesday's big drop. Analysts have expressed ...

Palantir shares have advanced 550% since January 2024, which makes it the best performing stock in the S&P 500 and the second ...

The Wall Street bank reiterated a Buy rating for Palantir and raised its forecast from $125 per share to $150, implying ...

IonQ has some overlap in the artificial intelligence (AI) space because quantum computers can be used to do things like AI ...

Although Palantir Technologies Inc. (PLTR) stock has a “nosebleed” valuation, it does look attractive, based on the ...

Palantir upped full-year guidance and delivered an above-consensus guide for Q2 FY 2025, thereby completing a triple play.

Another notable buy includes CRISPR Therapeutics AG (NASDAQ: CRSP ), with ARKK ETF purchasing 31,983 shares, reflecting a continued investment in the gene-editing company with a total dollar value of ...

Despite elevated volatility for the broader market, Palantir (NASDAQ: PLTR) stock saw explosive gains across April's trading.

RBC maintained its $40 target and ‘Underperform’ rating, citing concerns over Palantir’s product differentiation and long-term growth runway. The brokerage said the risk-reward profile remains skewed ...

Palantir (PLTR) stock fell 2% Friday morning and was set to post a 5% decline for the trading week amid continued concerns ...